Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Receives Average “Buy” Rating from Analysts


Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) has been assigned a consensus “Buy” recommendation by the eighteen rating companies that currently cover the company, MarketBeat reports. Three analysts rated the stock with a hold rating and nine assigned the company a buy rating. The 12-month average target price among analysts who have rated the stock over the past year is $206.47.

A number of analysts have recently commented on the company. Piper Sandler lowered its target price on Jazz Pharmaceuticals from $197.00 to $193.00 in a Thursday, May 5 research report. Cowen raised his price target on Jazz Pharmaceuticals from $200.00 to $225.00 in a Thursday, May 5 report. Cantor Fitzgerald reissued an “overweight” rating on Jazz Pharmaceuticals shares in a Wednesday, March 2 report. Royal Bank of Canada lowered its price target on Jazz Pharmaceuticals from $216.00 to $214.00 and set an “outperform” rating for the company in a Wednesday, March 2 report. Finally, StockNews.com upgraded Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a Tuesday, April 26 report.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 10,772 shares of the company in a trade that took place on Monday, April 4. The shares were sold at an average price of $158.33, for a total transaction of $1,705,530.76. Following completion of the transaction, the CEO now owns 346,062 shares of the company, valued at $54,791,996.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, CAO Patricia Carr sold 1,067 shares of the company in a trade that took place on Monday, May 9. The shares were sold at an average price of $148.94, for a total transaction of $158,918.98. As a result of the sale, the chief accounting officer now directly owns 7,229 shares of the company, valued at approximately $1,076,687.26. The disclosure of this sale can be found here. In the past 90 days, insiders have sold 22,330 shares of the company valued at $3,483,255. Insiders of the company own 4.30% of the shares of the company.

A number of large investors have recently bought and sold shares of JAZZ. Morgan Stanley increased its position in Jazz Pharmaceuticals by 81.1% in the second quarter. Morgan Stanley now owns 500,359 shares of the specialty pharmaceutical company worth $88,884,000 after purchasing an additional 224,068 shares during the period. Allianz Asset Management GmbH increased its stake in shares of Jazz Pharmaceuticals by 140.9% during the third quarter. Allianz Asset Management GmbH now owns 11,076 shares of the specialty pharmaceutical company worth $1,442,000 after acquiring 6,478 additional shares in the last quarter. First Republic Investment Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 5.9% during the third quarter. First Republic Investment Management Inc. now owns 9,880 shares of the specialty pharmaceutical company worth $1,286,000 after acquiring 550 additional shares in the last quarter. Oppenheimer Asset Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 1.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 5,746 shares of the specialty pharmaceutical company valued at $748,000 after buying 81 additional shares last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in the shares of Jazz Pharmaceuticals by 7.1% during the third quarter. The Manufacturers Life Insurance Company now owns 69,167 shares of the specialty pharmaceutical company valued at $9,006,000 after buying an additional 4,592 shares last quarter. 93.23% of the shares are held by institutional investors and hedge funds.

Shares of JAZZ opened at $150.91 on Friday. The company has a market capitalization of $9.40 billion, a PE ratio of -20.09, a PEG ratio of 1.24 and a beta of 0.79. Jazz Pharmaceuticals has a 12-month low of $117.64 and a 12-month high of $189.00. The stock’s 50-day moving average price is $156.91 and its two-hundred-day moving average price is $143.80. The company has a current ratio of 3.39, a quick ratio of 2.06 and a debt ratio of 1.66.

Jazz Pharmaceuticals Inc (NASDAQ:JAZZ – Get Rating) last released quarterly earnings data on Wednesday, May 4. The specialty pharmaceutical company reported earnings per share of $3.13 for the quarter, beating the consensus estimate of $3.00 by $0.13. Jazz Pharmaceuticals posted a positive return on equity of 22.45% and a negative net margin of 13.63%. The company posted revenue of $813.72 million in the quarter, versus analyst estimates of $853.73 million. During the same period last year, the company posted EPS of $3.42. The company’s quarterly revenue increased 33.9% year over year. Equity research analysts expect Jazz Pharmaceuticals to post EPS of 14.73 for the current fiscal year.

About Jazz Pharmaceuticals (Get an evaluation)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and markets pharmaceutical products for a variety of unmet medical needs in the United States, Europe and globally. The Company has a portfolio of products and product candidates focused on areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Read more

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ: JAZZ)



Get news and reviews for Jazz Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

About John Crowder

Check Also

Laila Biali says she’s ‘jazz for jazz skeptics’

READ MORE: JazzFest doesn’t miss a beat back from live shows Biali will perform on …